Showing results (281-290 of 317) with videos related to
Sort By:
Pageof 32
JHEP Reports : Innovation in Hepatology|October 16, 2025
Isolated IgG elevation in patients with persistently normal transaminases does not affect the outcome of autoimmune hepatitisÁlvaro Díaz-González, Ida Schregel, Lorena Carballo, et al.Gastroenterology|January 31, 2017
Metabolomic Identification of Subtypes of Nonalcoholic SteatohepatitisCristina Alonso, David Fernández-Ramos, Marta Varela-Rey, et al.Cell Metabolism|February 22, 2020
Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride AssemblyJorge Simon, Maitane Nuñez-García, Pablo Fernández-Tussy, et al.Cell Metabolism|February 24, 2026
Lack of PCK1 in hepatic stellate cells causes liver fibrosis by fueling tricarboxylic acid cycle and increasing glycolysisEva Novoa, Tamara Parracho, Julica Inderhees, et al.The Lancet. Gastroenterology & Hepatology|March 26, 2026
Binge drinking, metabolic dysfunction, and the spectrum of steatotic liver disease in the USA: a cross-sectional and longitudinal analysisZobair M Younossi, Aleksander Krag, Shira Zelber-Sagi, et al.United European Gastroenterology Journal|June 19, 2024
Fibroblast growth factor 21 is a hepatokine involved in MASLD progressionRocío Gallego-Durán, Javier Ampuero, Douglas Maya-Miles, et al.Molecular Metabolism|June 21, 2021
Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axisMarina Serrano-Maciá, Jorge Simón, Maria J González-Rellan, et al.Nature Reviews. Gastroenterology & Hepatology|October 28, 2021
Advancing the global public health agenda for NAFLD: a consensus statementJeffrey V Lazarus, Henry E Mark, Quentin M Anstee, et al.The Lancet. Gastroenterology & Hepatology|March 23, 2023
Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy studyYasaman Vali, Jenny Lee, Jerome Boursier, et al.Journal of Hepatology|July 22, 2025
Rivaroxaban to prevent complications of portal hypertension in cirrhosis: The CIRROXABAN studyÁngela Puente, Fanny Turón, Javier Martínez, et al.Pageof 32